“东方神药”青蒿素对抗药性疟疾还有效

2017-04-25 彭茜 杨舟 中国科学报

4月25日是世界防治疟疾日。近年来,疟疾的抗药性问题格外令人关注。屠呦呦等人发现的青蒿素一直被视为抗疟“东方神药”,但东南亚一些国家已发现对青蒿素有不同程度抗药性的疟原虫。专家对此表示,这并非意味着青蒿素完全无效,而是疟原虫对青蒿素的敏感性降低。世界卫生组织抗疟药物技术专家委员会主席、英国牛津大学教授尼古拉斯·怀特在接受记者专访时说,由于青蒿素最早用于东南亚地区,所以该地区的柬埔寨等国最早出现了抗

4月25日是世界防治疟疾日。近年来,疟疾的抗药性问题格外令人关注。屠呦呦等人发现的青蒿素一直被视为抗疟“东方神药”,但东南亚一些国家已发现对青蒿素有不同程度抗药性的疟原虫。专家对此表示,这并非意味着青蒿素完全无效,而是疟原虫对青蒿素的敏感性降低。

世界卫生组织抗疟药物技术专家委员会主席、英国牛津大学教授尼古拉斯·怀特在接受记者专访时说,由于青蒿素最早用于东南亚地区,所以该地区的柬埔寨等国最早出现了抗药性问题。但怀特强调,认为复方青蒿素抗疟药疗法(ACT)失效为时尚早,找到抗疟新药还需要一个漫长过程,ACT目前仍然是对抗疟疾的最有效手段。

为应对抗药性问题,怀特和玛希隆-牛津热带医学研究所的同事正在致力于研究新的ACT疗法。与两种青蒿素类药物组成的传统ACT疗法相比,他们的最新研究采用了三种药物的联合疗法,治疗疟疾更有效。

“现在我们说的青蒿素抗药性其实是指疟原虫对青蒿素的敏感性降低,而并非完全无效。科学家的研究表明,如果将现行青蒿素类药物的疗程由3天延长到7天,绝大部分的疟原虫还是可以被杀死的。”吴以芳同样指出。

。吴以芳说,疟疾流行地区基本都是经济欠发达的偏远地区,当地市场的青蒿素类药物品牌很多,质量参差不齐,如果用药剂量和疗程不规范,也会影响到治疗效果。

怀特还表示,对青蒿素抗药性的研究应引起更多重视,否则“就会真正失去这种有价值的药物”。上世纪60年代,泰柬边境首先出现了对疟疾特效药氯喹产生抗药性的恶性疟疾,随后扩散到整个东南亚直至非洲;如今,对青蒿素产生抗药性的疟原虫从亚洲传播到非洲的风险也非常高。

怀特说,与SARS、H5N1禽流感等传染病主要在城市传播不同,疟疾感染者大多生活在偏远乡村等不发达地区,因此未能引起全球高度关注。他呼吁相关政府机构和国际组织在抗疟行动中拿出更强有力的、透明化的管理和决策,并指出,中国在消除疟疾方面的执行力值得借鉴和学习。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1495375, encodeId=2eda14953e5e1, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Apr 27 13:13:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190745, encodeId=d5f7190e452a, content=归根结底在于规范用药上, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xwU6047w4GQZHmaJMe3cGxCqPS0x43a9R04dN3HrAn5diaR2N4pEwoibqiaiaA3m6ia3g3XbZXadIomlRa5WAvjSUHb/0, createdBy=93aa1715091, createdName=为啥子, createdTime=Wed Apr 26 11:03:24 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190716, encodeId=df85190e16ec, content=耐药后还有人的抵抗力, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7lBrMCuvxicCR3XJQhu2X3SmEzicSFDknz19Vav0ln3PHYSicIKQRIiazzcibtEchpeQNrjh2jfOYC0w/132, createdBy=eb931929187, createdName=美丽明天在等我, createdTime=Wed Apr 26 08:59:23 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190690, encodeId=4c8d1906909c, content=疟疾的抗药性问题格外令人关注。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Apr 26 08:30:20 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190665, encodeId=b3661906657c, content=学习了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhQkEvDREF6S2vZq3ZIpUYjdqicKVoAWaJSGoe8xNvS6o6QpmOlh2AQ7xuUpj8NiaDjJJgjbc7Xj3T6/0, createdBy=1c242047915, createdName=daiyaozu, createdTime=Wed Apr 26 07:57:45 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190603, encodeId=2a39190603cc, content=阅读了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Apr 26 05:37:14 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190573, encodeId=21f81905e39b, content=世间现在还是一物降一物吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Apr 25 23:30:18 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190563, encodeId=d1d519056347, content=学习受益良多非常的感谢领导和同事非常感谢楼主, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220814/be36b1918b4c4eeba48ae6c167571ce9/3bd4e17f256d4fdba54abc66bb0f616c.jpg, createdBy=a4042044999, createdName=jiangwei200908, createdTime=Tue Apr 25 23:13:59 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190549, encodeId=322019054986, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 25 22:44:34 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-27 songbq
  2. [GetPortalCommentsPageByObjectIdResponse(id=1495375, encodeId=2eda14953e5e1, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Apr 27 13:13:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190745, encodeId=d5f7190e452a, content=归根结底在于规范用药上, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xwU6047w4GQZHmaJMe3cGxCqPS0x43a9R04dN3HrAn5diaR2N4pEwoibqiaiaA3m6ia3g3XbZXadIomlRa5WAvjSUHb/0, createdBy=93aa1715091, createdName=为啥子, createdTime=Wed Apr 26 11:03:24 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190716, encodeId=df85190e16ec, content=耐药后还有人的抵抗力, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7lBrMCuvxicCR3XJQhu2X3SmEzicSFDknz19Vav0ln3PHYSicIKQRIiazzcibtEchpeQNrjh2jfOYC0w/132, createdBy=eb931929187, createdName=美丽明天在等我, createdTime=Wed Apr 26 08:59:23 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190690, encodeId=4c8d1906909c, content=疟疾的抗药性问题格外令人关注。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Apr 26 08:30:20 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190665, encodeId=b3661906657c, content=学习了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhQkEvDREF6S2vZq3ZIpUYjdqicKVoAWaJSGoe8xNvS6o6QpmOlh2AQ7xuUpj8NiaDjJJgjbc7Xj3T6/0, createdBy=1c242047915, createdName=daiyaozu, createdTime=Wed Apr 26 07:57:45 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190603, encodeId=2a39190603cc, content=阅读了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Apr 26 05:37:14 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190573, encodeId=21f81905e39b, content=世间现在还是一物降一物吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Apr 25 23:30:18 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190563, encodeId=d1d519056347, content=学习受益良多非常的感谢领导和同事非常感谢楼主, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220814/be36b1918b4c4eeba48ae6c167571ce9/3bd4e17f256d4fdba54abc66bb0f616c.jpg, createdBy=a4042044999, createdName=jiangwei200908, createdTime=Tue Apr 25 23:13:59 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190549, encodeId=322019054986, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 25 22:44:34 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-26 为啥子

    归根结底在于规范用药上

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1495375, encodeId=2eda14953e5e1, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Apr 27 13:13:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190745, encodeId=d5f7190e452a, content=归根结底在于规范用药上, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xwU6047w4GQZHmaJMe3cGxCqPS0x43a9R04dN3HrAn5diaR2N4pEwoibqiaiaA3m6ia3g3XbZXadIomlRa5WAvjSUHb/0, createdBy=93aa1715091, createdName=为啥子, createdTime=Wed Apr 26 11:03:24 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190716, encodeId=df85190e16ec, content=耐药后还有人的抵抗力, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7lBrMCuvxicCR3XJQhu2X3SmEzicSFDknz19Vav0ln3PHYSicIKQRIiazzcibtEchpeQNrjh2jfOYC0w/132, createdBy=eb931929187, createdName=美丽明天在等我, createdTime=Wed Apr 26 08:59:23 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190690, encodeId=4c8d1906909c, content=疟疾的抗药性问题格外令人关注。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Apr 26 08:30:20 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190665, encodeId=b3661906657c, content=学习了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhQkEvDREF6S2vZq3ZIpUYjdqicKVoAWaJSGoe8xNvS6o6QpmOlh2AQ7xuUpj8NiaDjJJgjbc7Xj3T6/0, createdBy=1c242047915, createdName=daiyaozu, createdTime=Wed Apr 26 07:57:45 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190603, encodeId=2a39190603cc, content=阅读了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Apr 26 05:37:14 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190573, encodeId=21f81905e39b, content=世间现在还是一物降一物吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Apr 25 23:30:18 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190563, encodeId=d1d519056347, content=学习受益良多非常的感谢领导和同事非常感谢楼主, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220814/be36b1918b4c4eeba48ae6c167571ce9/3bd4e17f256d4fdba54abc66bb0f616c.jpg, createdBy=a4042044999, createdName=jiangwei200908, createdTime=Tue Apr 25 23:13:59 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190549, encodeId=322019054986, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 25 22:44:34 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-26 美丽明天在等我

    耐药后还有人的抵抗力

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1495375, encodeId=2eda14953e5e1, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Apr 27 13:13:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190745, encodeId=d5f7190e452a, content=归根结底在于规范用药上, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xwU6047w4GQZHmaJMe3cGxCqPS0x43a9R04dN3HrAn5diaR2N4pEwoibqiaiaA3m6ia3g3XbZXadIomlRa5WAvjSUHb/0, createdBy=93aa1715091, createdName=为啥子, createdTime=Wed Apr 26 11:03:24 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190716, encodeId=df85190e16ec, content=耐药后还有人的抵抗力, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7lBrMCuvxicCR3XJQhu2X3SmEzicSFDknz19Vav0ln3PHYSicIKQRIiazzcibtEchpeQNrjh2jfOYC0w/132, createdBy=eb931929187, createdName=美丽明天在等我, createdTime=Wed Apr 26 08:59:23 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190690, encodeId=4c8d1906909c, content=疟疾的抗药性问题格外令人关注。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Apr 26 08:30:20 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190665, encodeId=b3661906657c, content=学习了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhQkEvDREF6S2vZq3ZIpUYjdqicKVoAWaJSGoe8xNvS6o6QpmOlh2AQ7xuUpj8NiaDjJJgjbc7Xj3T6/0, createdBy=1c242047915, createdName=daiyaozu, createdTime=Wed Apr 26 07:57:45 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190603, encodeId=2a39190603cc, content=阅读了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Apr 26 05:37:14 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190573, encodeId=21f81905e39b, content=世间现在还是一物降一物吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Apr 25 23:30:18 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190563, encodeId=d1d519056347, content=学习受益良多非常的感谢领导和同事非常感谢楼主, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220814/be36b1918b4c4eeba48ae6c167571ce9/3bd4e17f256d4fdba54abc66bb0f616c.jpg, createdBy=a4042044999, createdName=jiangwei200908, createdTime=Tue Apr 25 23:13:59 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190549, encodeId=322019054986, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 25 22:44:34 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-26 cqykthl

    疟疾的抗药性问题格外令人关注。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1495375, encodeId=2eda14953e5e1, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Apr 27 13:13:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190745, encodeId=d5f7190e452a, content=归根结底在于规范用药上, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xwU6047w4GQZHmaJMe3cGxCqPS0x43a9R04dN3HrAn5diaR2N4pEwoibqiaiaA3m6ia3g3XbZXadIomlRa5WAvjSUHb/0, createdBy=93aa1715091, createdName=为啥子, createdTime=Wed Apr 26 11:03:24 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190716, encodeId=df85190e16ec, content=耐药后还有人的抵抗力, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7lBrMCuvxicCR3XJQhu2X3SmEzicSFDknz19Vav0ln3PHYSicIKQRIiazzcibtEchpeQNrjh2jfOYC0w/132, createdBy=eb931929187, createdName=美丽明天在等我, createdTime=Wed Apr 26 08:59:23 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190690, encodeId=4c8d1906909c, content=疟疾的抗药性问题格外令人关注。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Apr 26 08:30:20 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190665, encodeId=b3661906657c, content=学习了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhQkEvDREF6S2vZq3ZIpUYjdqicKVoAWaJSGoe8xNvS6o6QpmOlh2AQ7xuUpj8NiaDjJJgjbc7Xj3T6/0, createdBy=1c242047915, createdName=daiyaozu, createdTime=Wed Apr 26 07:57:45 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190603, encodeId=2a39190603cc, content=阅读了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Apr 26 05:37:14 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190573, encodeId=21f81905e39b, content=世间现在还是一物降一物吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Apr 25 23:30:18 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190563, encodeId=d1d519056347, content=学习受益良多非常的感谢领导和同事非常感谢楼主, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220814/be36b1918b4c4eeba48ae6c167571ce9/3bd4e17f256d4fdba54abc66bb0f616c.jpg, createdBy=a4042044999, createdName=jiangwei200908, createdTime=Tue Apr 25 23:13:59 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190549, encodeId=322019054986, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 25 22:44:34 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-26 daiyaozu

    学习了,不错

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1495375, encodeId=2eda14953e5e1, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Apr 27 13:13:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190745, encodeId=d5f7190e452a, content=归根结底在于规范用药上, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xwU6047w4GQZHmaJMe3cGxCqPS0x43a9R04dN3HrAn5diaR2N4pEwoibqiaiaA3m6ia3g3XbZXadIomlRa5WAvjSUHb/0, createdBy=93aa1715091, createdName=为啥子, createdTime=Wed Apr 26 11:03:24 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190716, encodeId=df85190e16ec, content=耐药后还有人的抵抗力, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7lBrMCuvxicCR3XJQhu2X3SmEzicSFDknz19Vav0ln3PHYSicIKQRIiazzcibtEchpeQNrjh2jfOYC0w/132, createdBy=eb931929187, createdName=美丽明天在等我, createdTime=Wed Apr 26 08:59:23 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190690, encodeId=4c8d1906909c, content=疟疾的抗药性问题格外令人关注。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Apr 26 08:30:20 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190665, encodeId=b3661906657c, content=学习了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhQkEvDREF6S2vZq3ZIpUYjdqicKVoAWaJSGoe8xNvS6o6QpmOlh2AQ7xuUpj8NiaDjJJgjbc7Xj3T6/0, createdBy=1c242047915, createdName=daiyaozu, createdTime=Wed Apr 26 07:57:45 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190603, encodeId=2a39190603cc, content=阅读了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Apr 26 05:37:14 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190573, encodeId=21f81905e39b, content=世间现在还是一物降一物吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Apr 25 23:30:18 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190563, encodeId=d1d519056347, content=学习受益良多非常的感谢领导和同事非常感谢楼主, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220814/be36b1918b4c4eeba48ae6c167571ce9/3bd4e17f256d4fdba54abc66bb0f616c.jpg, createdBy=a4042044999, createdName=jiangwei200908, createdTime=Tue Apr 25 23:13:59 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190549, encodeId=322019054986, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 25 22:44:34 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-26 刘煜

    阅读了谢谢分享。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1495375, encodeId=2eda14953e5e1, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Apr 27 13:13:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190745, encodeId=d5f7190e452a, content=归根结底在于规范用药上, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xwU6047w4GQZHmaJMe3cGxCqPS0x43a9R04dN3HrAn5diaR2N4pEwoibqiaiaA3m6ia3g3XbZXadIomlRa5WAvjSUHb/0, createdBy=93aa1715091, createdName=为啥子, createdTime=Wed Apr 26 11:03:24 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190716, encodeId=df85190e16ec, content=耐药后还有人的抵抗力, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7lBrMCuvxicCR3XJQhu2X3SmEzicSFDknz19Vav0ln3PHYSicIKQRIiazzcibtEchpeQNrjh2jfOYC0w/132, createdBy=eb931929187, createdName=美丽明天在等我, createdTime=Wed Apr 26 08:59:23 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190690, encodeId=4c8d1906909c, content=疟疾的抗药性问题格外令人关注。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Apr 26 08:30:20 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190665, encodeId=b3661906657c, content=学习了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhQkEvDREF6S2vZq3ZIpUYjdqicKVoAWaJSGoe8xNvS6o6QpmOlh2AQ7xuUpj8NiaDjJJgjbc7Xj3T6/0, createdBy=1c242047915, createdName=daiyaozu, createdTime=Wed Apr 26 07:57:45 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190603, encodeId=2a39190603cc, content=阅读了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Apr 26 05:37:14 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190573, encodeId=21f81905e39b, content=世间现在还是一物降一物吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Apr 25 23:30:18 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190563, encodeId=d1d519056347, content=学习受益良多非常的感谢领导和同事非常感谢楼主, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220814/be36b1918b4c4eeba48ae6c167571ce9/3bd4e17f256d4fdba54abc66bb0f616c.jpg, createdBy=a4042044999, createdName=jiangwei200908, createdTime=Tue Apr 25 23:13:59 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190549, encodeId=322019054986, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 25 22:44:34 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-25 lyh994

    世间现在还是一物降一物吗?

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1495375, encodeId=2eda14953e5e1, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Apr 27 13:13:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190745, encodeId=d5f7190e452a, content=归根结底在于规范用药上, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xwU6047w4GQZHmaJMe3cGxCqPS0x43a9R04dN3HrAn5diaR2N4pEwoibqiaiaA3m6ia3g3XbZXadIomlRa5WAvjSUHb/0, createdBy=93aa1715091, createdName=为啥子, createdTime=Wed Apr 26 11:03:24 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190716, encodeId=df85190e16ec, content=耐药后还有人的抵抗力, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7lBrMCuvxicCR3XJQhu2X3SmEzicSFDknz19Vav0ln3PHYSicIKQRIiazzcibtEchpeQNrjh2jfOYC0w/132, createdBy=eb931929187, createdName=美丽明天在等我, createdTime=Wed Apr 26 08:59:23 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190690, encodeId=4c8d1906909c, content=疟疾的抗药性问题格外令人关注。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Apr 26 08:30:20 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190665, encodeId=b3661906657c, content=学习了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhQkEvDREF6S2vZq3ZIpUYjdqicKVoAWaJSGoe8xNvS6o6QpmOlh2AQ7xuUpj8NiaDjJJgjbc7Xj3T6/0, createdBy=1c242047915, createdName=daiyaozu, createdTime=Wed Apr 26 07:57:45 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190603, encodeId=2a39190603cc, content=阅读了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Apr 26 05:37:14 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190573, encodeId=21f81905e39b, content=世间现在还是一物降一物吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Apr 25 23:30:18 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190563, encodeId=d1d519056347, content=学习受益良多非常的感谢领导和同事非常感谢楼主, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220814/be36b1918b4c4eeba48ae6c167571ce9/3bd4e17f256d4fdba54abc66bb0f616c.jpg, createdBy=a4042044999, createdName=jiangwei200908, createdTime=Tue Apr 25 23:13:59 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190549, encodeId=322019054986, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 25 22:44:34 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-25 jiangwei200908

    学习受益良多非常的感谢领导和同事非常感谢楼主

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1495375, encodeId=2eda14953e5e1, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Apr 27 13:13:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190745, encodeId=d5f7190e452a, content=归根结底在于规范用药上, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xwU6047w4GQZHmaJMe3cGxCqPS0x43a9R04dN3HrAn5diaR2N4pEwoibqiaiaA3m6ia3g3XbZXadIomlRa5WAvjSUHb/0, createdBy=93aa1715091, createdName=为啥子, createdTime=Wed Apr 26 11:03:24 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190716, encodeId=df85190e16ec, content=耐药后还有人的抵抗力, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7lBrMCuvxicCR3XJQhu2X3SmEzicSFDknz19Vav0ln3PHYSicIKQRIiazzcibtEchpeQNrjh2jfOYC0w/132, createdBy=eb931929187, createdName=美丽明天在等我, createdTime=Wed Apr 26 08:59:23 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190690, encodeId=4c8d1906909c, content=疟疾的抗药性问题格外令人关注。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Apr 26 08:30:20 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190665, encodeId=b3661906657c, content=学习了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhQkEvDREF6S2vZq3ZIpUYjdqicKVoAWaJSGoe8xNvS6o6QpmOlh2AQ7xuUpj8NiaDjJJgjbc7Xj3T6/0, createdBy=1c242047915, createdName=daiyaozu, createdTime=Wed Apr 26 07:57:45 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190603, encodeId=2a39190603cc, content=阅读了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Apr 26 05:37:14 CST 2017, time=2017-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190573, encodeId=21f81905e39b, content=世间现在还是一物降一物吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Apr 25 23:30:18 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190563, encodeId=d1d519056347, content=学习受益良多非常的感谢领导和同事非常感谢楼主, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220814/be36b1918b4c4eeba48ae6c167571ce9/3bd4e17f256d4fdba54abc66bb0f616c.jpg, createdBy=a4042044999, createdName=jiangwei200908, createdTime=Tue Apr 25 23:13:59 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190549, encodeId=322019054986, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 25 22:44:34 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-25 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

相关资讯

Phytomedicine:植物粉末挽救了生命垂危的疟疾患者

现在科学家已发现对青蒿素有不同程度抗药性的疟原虫。事实上,世界卫生组织曾表示,感染人类的五种疟原虫中有三种已对主要抗疟药物产生耐药性。所以当刚果的 18 名患者对治疗疟疾的常规药物没有反应时,医生知道他们必须采取行动来尝试不同的治疗方案。他们不是选择使用更多的合成药,而是转向大自然,并找到了一个取得了显着成果的解决方案。医生首先用世界卫生组织(WHO)推荐的方案治疗患者:青蒿素药物联合疗法 (AC

Cell:糖尿病研究重大突破!青蒿素可让α细胞产生胰岛素

一种简单而又优雅的策略有望治疗1型糖尿病:在病人体内,利用新产生的分泌胰岛素的细胞替换受到破坏的β细胞。多年来,为了诱导这种转化,全世界的科学家们已利用干细胞或成体细胞尝试过多种方法。他们的努力已导致人们对参与β细胞发育的分子机制有了基本了解,然而能够成功实现这一点的化合物是缺乏的。奥地利科学院CeMM分子医学研究中心小组领导者Stefan Kubicek及其团队最终取得领先:在他们最新的发表在C

Ann Surg:屠呦呦青蒿琥酯的又一重大临床作用!

大鼠出血性休克(HS)仍然是严重受伤患者的常见死亡原因,其特征是器官灌注受损、全身炎症反应和多器官功能衰竭。目前没有减少器官损伤/功能障碍的特定疗法。青蒿琥酯除了其抗疟活性的药理作用,还有例如抗癌,抗病毒和抗炎作用。近期,一项发表在Ann Surg杂志上的研究评估青蒿琥酯对HS相关的器官损伤和功能障碍的影响。首先建立了HS大鼠模型。使大鼠的平均动脉压降低至30mmHg 维持90分钟,然后复苏。大鼠

N Engl J Med:非洲本地恶性疟原虫对青蒿素抗性的出现

青蒿素是在大多数国家是治疗疟疾的一线药物,在疟疾流行的非洲其作用显得尤为重要。然而随着恶性疟原虫已经在东南亚的许多国家对青蒿素的抗性的出现,国际社会开始高度关注青蒿素在非洲的抗性情况。在赤道几内亚,疟疾流行率一直很高,青蒿素联合治疗作为最常用的治疗方式。在赤道几内亚和具有类似疟疾传播的非洲国家中,应该警惕非洲恶性疟对青蒿素的耐药性,监测潜在的青蒿素抗性出现。

4月25日世界防治疟疾日 盘点疟疾研究重大进展

疟疾是经按蚊叮咬或输入带疟原虫者的血液而感染疟原虫所引起的虫媒传染病。寄生于人体的疟原虫共有五种,即间日疟原虫,三日疟原虫,恶性疟原虫、卵形疟原虫和诺氏疟原虫。一旦疟原虫通过蚊子叮咬进入人体,它们先在肝脏中增殖,随后侵入红细胞,在那里,它们导致所有的疟疾症状。疟疾能通过受感染的蚊虫叮咬传播,影响了世界上97个国家和地区。

LANCET INFECT DIS:大湄公河次区域青蒿素抗性的传播

在这项观察性研究中,研究人员检测了缅甸东北部的恶性疟原虫分离株,老挝南部和柬埔寨西部的PfKelch13突变和Pfplasmepsin2基因扩增(表明哌喹抗性)。研究人员根据显微镜镜检或快速诊断试剂从非重症恶性疟的患者中收集血样,并使用微卫星基因分型来评估遗传相关性。